# AstraZeneca-CICC Venture Capital

> AstraZeneca-CICC Venture Capital is a VC fund in Beijing backing Biotechnology and Biopharma. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Beijing, China
- Total investments: 5
- Last investment: Sep 2025
- Lead investor: 100%
- Last updated: Aug 2026

AstraZeneca-CICC Venture Capital is a Global Healthcare Industrial Fund formed by AstraZeneca and China International Capital Corporation.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 60% |
| Biopharma | 2 | 40% |
| Medical | 1 | 20% |
| Pharmaceutical | 1 | 20% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 40% |
| Series C | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 2 | 40% |
| United States | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| YolTech Therapeutics | Yaotang (Shanghai) Biotechnology is a high-tech biotechnology company focusing on developing a new generation of mRNA drugs and gene editing drugs by combining mRNA in vivo delivery technology and gene editing technology. Through the continuous development and optimization of CRISPR, base editing and other new-generation gene editing tools, andinnovative improvements to the next-generation mRNA production platform and lipid nanocarrier assembly process, Yaotang Bio is committed to developing treatments for genetic diseases and cardiovascular disease. | $42.1M | Series B | Sep 11, 2025 |  |
| YolTech Therapeutics | Yaotang (Shanghai) Biotechnology is a high-tech biotechnology company focusing on developing a new generation of mRNA drugs and gene editing drugs by combining mRNA in vivo delivery technology and gene editing technology. Through the continuous development and optimization of CRISPR, base editing and other new-generation gene editing tools, andinnovative improvements to the next-generation mRNA production platform and lipid nanocarrier assembly process, Yaotang Bio is committed to developing treatments for genetic diseases and cardiovascular disease. | $42.1M | Series B | Sep 11, 2025 |  |
| Cullgen | Cullgen is a drug discovery service intended to create new drugs for the treatment of diseases that currently lack effective therapies. The company's services use protein degradation technology that focuses on the selective degradation of disease-causing proteins, a novel treatment for cancer, inflammatory and autoimmune diseases, includingtargets previously considered undruggable, enabling scientists with new means to develop novel therapeutic approaches for various diseases. | $35M | Series C | May 08, 2023 |  |
| Cullgen | Cullgen is a drug discovery service intended to create new drugs for the treatment of diseases that currently lack effective therapies. The company's services use protein degradation technology that focuses on the selective degradation of disease-causing proteins, a novel treatment for cancer, inflammatory and autoimmune diseases, includingtargets previously considered undruggable, enabling scientists with new means to develop novel therapeutic approaches for various diseases. | $35M | Series C | May 08, 2023 |  |
| Etern | Etern is developing small molecule drugs for protein liquid-liquid phase separation, using the LLPS platform for AI-enabled target discovery, high-throughput screening, and optimization. This could open new treatment strategies for major diseases. |  | Series B | Aug 31, 2021 |  |

5 of 5 investments shown.

## Co-investors
- [Green Pine Capital Partners](https://shizune.co/investors/profile/green-pine-capital-partners) — VC Fund, 4 deals together
- [Core Energy Ventures](https://shizune.co/investors/profile/core-energy-ventures) — VC Fund, 2 deals together
- [Decheng Capital](https://shizune.co/investors/profile/decheng-capital) — VC Fund, 2 deals together
- [GNI Japan](https://shizune.co/investors/profile/gni-japan) — VC Fund, 2 deals together
- [Grand Flight Investment](https://shizune.co/investors/profile/grand-fight-investment) — VC Fund, 2 deals together
- [Guoke New Energy Venture Capital](https://shizune.co/investors/profile/guoke-new-energy-venture-capital) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does AstraZeneca-CICC Venture Capital invest in?

AstraZeneca-CICC Venture Capital invests primarily in Biotechnology, Biopharma and Medical startups, most often at Series B and Series C stage. Most of the 5 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did AstraZeneca-CICC Venture Capital last invest?

The most recent investment recorded for AstraZeneca-CICC Venture Capital closed in Sep 2025. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co